drugset / Trial / NCT01924143

TD-9855 Mass Balance Study

NCT01924143

Phase 1 Completed 6 enrolled Theravance Biopharma
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]TD-9855

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ampreloxetine Small molecule 20 mg Oral